Ivanna Rosendal

Lab to Lives

A simple question started this show: How do we medicine from the lab to making a difference in people's lives as quickly as possible?  The answers are complex. Actual solutions are hard to come by. We want to distill ideas until we see actual impact in the industry.  Our three hosts all have backgrounds in life sciences and in improv comedy. Together, with their guests, they're on a mission to have conversations that can have an impact. And have some fun along the way.

Koniecznie odwiedź stronę podcastu i wesprzyj twórcę: www.labtolives.com

Autor

Ivanna Rosendal

Kategoria

Science

Strona podcastu

www.labtolives.com

Ostatni odcinek

18 lis 2026

Gdzie słuchać?

Podcasty w aplikacji Replaio Radio Już wkrótce

Podcasty trafią do aplikacji już wkrótce. Zainstaluj teraz i jako pierwszy zobacz nowe podejście do podcastów

Pobierz z Google Play Zainstaluj za darmo Android 10 mln+ pobrań · ocena 4,7+ iOS wkrótce

Odcinki

How Fast Can You Move, If You Fund Your Own Lab w. Roopa Reddy 18.11.2026

Send us Fan Mail Drug discovery is getting pulled in two directions at once: east towards China’s rapidly maturing innovation engine, and forward into a new wave of AI partnerships that promise faster trials, smarter pipelines, and better use of old data. We kick off by unpacking what we heard on the ground at a Copenhagen biotech conference, including the growing outlicensing of China-invented dr...

How Much Does Your Life Cost w/ Stuart Berkowitz 11.11.2026

Send us Fan Mail Most teams in pharma say they want breakthrough impact, yet R&D portfolios keep clustering around the familiar. That tension is where our conversation with Stuart Berkowitz gets practical fast: if a disease area is already “98% served” by existing interventions, why sink a decade into a new molecule that barely moves the needle? We dig into how biology is changing shape as a f...

How To Turn Stalled Research Into Treatments For Ultra-Rare Diseases w/ Stephanie Manton 04.11.2026

Send us Fan Mail A therapy can be scientifically obvious and still never reach a patient. That contradiction is the centre of our conversation with Stephanie , CEO of WinQure Medicine , where we pull apart what really breaks when you try to develop drugs for ultra-rare disease, including “nano-rare” patients who may be one in a million. We start with the lived reality: parents and carers who becom...

Scaling Science Without Losing The Plot w/ Jennifer Man 21.10.2026

Send us Fan Mail 12 million samples at minus 80 is not a fun fact, it is a daily responsibility. We sit down with Jennifer Man, Scientific Director at UK Biocentre in Milton Keynes, to unpack what “lab to lives” really demands once science meets real-world scale: operational readiness, rigorous compliance, and systems that protect patient samples while still moving fast enough to serve national re...

Clinical Trials Move Faster When Sites Get Paid On Time 14.10.2026

Send us Fan Mail A clinical trial can have brilliant science and still stall for a painfully ordinary reason: the site does not get paid on time. We sit down with Patrick Mizer and Kevin Williams from LedgerRun to unpack why clinical trial site payments and contracts become a hidden bottleneck, how that pressure lands on research sites, and why sponsors and CROs only notice the “back office” when...

If Your Medicine Arrives With A Screwdriver, It is Counterfeit w/ David Chametzky 14.10.2026

Send us Fan Mail A medicine can look perfect and still be wrong, and that gap between appearance and reality is where patients get hurt. We sit down with Dave Chametzky, who spent decades working alongside the pharmaceutical industry’s legal and protection efforts, to talk candidly about counterfeit drugs, how quickly fakes can hit the market, and what everyday buyers can do to lower their risk wh...

Trailer 09.10.2026

Send us Fan Mail Support the show ________ Reach out to Ivanna Rosendal Join the conversation on our LinkedIn page Visit www.labtolives.com   Hosts Alexander Booth Chiara Chianese Ivanna Rosendal Oshida  

Male Fertility in The Human Being Room w/ Chiara Chianese 07.10.2026

Send us Fan Mail If you have ever wondered why brilliant healthcare ideas still fail to reach patients, this conversation gets uncomfortably specific, in the best way. We sit down with Chiara, a former wet-lab genomics scientist who worked in male infertility, then pivoted into an MBA, startups, and pharma strategy roles in AI and analytics. She now co-founds Orby Grants to make grant writing and...

How Many Alexes Does It Take To Launch A Drug w/ Daphne Smyth 30.09.2026

Send us Fan Mail Europe looks like one market on a map, but try bringing a drug across borders and you quickly learn it behaves like many systems at once. We sit down with Daphne Smyth, a regulatory leader based in Ireland with 35+ years in pharmaceutical regulatory affairs, to unpack a mistake we keep seeing: companies build commercial teams first, then discover they have not built the regulatory...

Pharma Wants A Cupcake But Gets Ingredients w/ Dr. Isabelle Widmer 02.09.2026

Send us Fan Mail Pharma doesn’t usually fail because the science is too hard. It stalls because humans are trying to do hard work inside a system that is overloaded, siloed and full of unwritten rules. We sit down with Isabelle, a physician with deep pharma experience who now works as a consultant, to unpack what really stops transformation and what actually helps teams move again.  We talk about...

Enabling Clinical Trial Technology that Cuts Risk and Speeds Patient Access 26.08.2026

Send us Fan Mail Clinical trials are meant to generate evidence, not paperwork, but too many studies still depend on spreadsheets, duplicate data entry and unconnected systems. This episode we are joined by Karen Maduschke, a clinical trial technology leader with over 20 years of experience, from building one of the first interactive e-consent products to scaling trial tech through acquisition and...

The Emperor’s Naked And The Trial’s Still On w/ Dr. Grant Coren 08.07.2026

Send us Fan Mail “Patients first” sounds simple until you follow the incentives. We’re joined by Dr Grant Coren, a genetics-trained PhD who moved from cancer research into decades of recruiting talent across the pharmaceutical industry and biotech. Together, we ask the uncomfortable question that sits under mission statements and glossy brand values: do pharma organisations truly value patients ov...

What If The Real Blocker Is Coordination Not Data w/ Anastasia Christianson 10.06.2026

Send us Fan Mail AI is everywhere in pharma right now, yet drug development still feels slow, fragmented, and full of avoidable rework. We sit down with Anastasia Christianson, former SVP and Global Head of AI Data and Analytics at Pfizer and now Managing Principal at EPAM Life Science Consulting, to get specific about what actually blocks progress in clinical trials and what AI can realistically...

Electrifying the Factory: Agentic AI For Faster Clinical Trials with Pamela Tenaerts 13.05.2026

Send us Fan Mail The clinical trial system is starting to look like a motorway at a standstill: more and more drugs are lining up, but the lanes ahead are already full. We sit down with Pamela Tenart to unpack why the industry may have reached the limit of human-only clinical development, and why “adding more people” is no longer a realistic plan when experienced CRAs, site co-ordinators and trial...

Why Big Pharma Feels Like A Financial Institution & Don't Pee on Medical Gloves with Anish Shindore 15.04.2026

Send us Fan Mail A medicine can be proven safe and effective, approved by regulators, and still fail the one test that matters: actually reaching patients in the real world. We sit down with Anish, a deep commercial thinker, to unpack what pharmaceutical commercialisation really is when you strip away the slogans and look at incentives, bottlenecks, and human behaviour.  We start with our five val...

How Biotech Ideas Become Real Patient Impact w/ new co-hosts Alex and Dimitri 30.03.2026

Send us Fan Mail This is the first episode in the rebranded show! Drug and medical device breakthroughs do not reach patients because they’re clever in a lab. They reach patients when innovation, regulatory strategy, partnerships, clinical evidence and commercial reality line up at the same time, and that’s where things get messy. We’re launching Lab to Lives with a simple goal: talk honestly abou...

Dear Pharma, Your Patient Isn’t A KPI with Mark Duman 03.03.2026

Send us Fan Mail What happens when we stop calling people “subjects” and start inviting them to help build the solutions they need? We sit down with pharmacist and patient engagement leader Mark Duman to unpack how language, literacy, and lived experience can transform clinical trials, medtech, and digital health from the ground up. Mark introduces his three Cs—co-creation, choice, and coaching—an...

Audit Trails, RBQM, And Agentic AI Explained 11.02.2026

Send us Fan Mail Ever wondered why a clean CSR still leaves you unsure how a trial actually ran? We dive into the hidden layer that explains the “how”: audit trails across EDC, IRT, eConsent, and ePRO. With guests Ellis Hiroki of Study OS (now rebranded  siteroAI) and Nechama Katan of Wicked Problem Wizard, we unpack how E6(R3) shifts sponsors from “we can export logs” to “we continuously analyse...

Why Bringing The Trial To The Patient Beats Dragging Patients To Sites 28.01.2026

Send us Fan Mail Want clinical research that respects real life? We sit down with Caroline Potts, GM of Site and Patient Services at MRN, to rethink how patients are recruited and supported when the standard trial model collides with work, school, caregiving, and distance. We start at the site level, exploring why trial sites remain the beating heart of studies, then unpack how participants actual...

Inside Sionna’s Bid To Normalize CFTR Function 17.12.2025

Send us Fan Mail Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star. Visit: sionnatx.com Visit Labtolives...

AI Won’t Replace Writers, But Writers Who Use AI Will Outpace The Rest with Bilal Bham 03.12.2025

Send us Fan Mail What if the documents behind a clinical trial were written with the patient’s voice in mind and delivered at the speed modern science deserves? We sit down with writer, consultant, and patient-advocate Bilal Bham to unpack how protocols, clinical trial applications, and clinical study reports actually get made, why structure beats chaos, and where AI genuinely shortens timelines w...

From Grief To Global Advocacy For Clinical Research In Infectious Diseases with Christian John Lillis 19.11.2025

Send us Fan Mail A routine dental visit, a few days of diarrhea, and then the unthinkable: septic shock and a life lost within 24 hours. Our guest, Christian John Lillis, shares how losing his mother Peggy to a community-acquired C. diff infection exposed a silent public health crisis and led him to co-found the Peggy Lillis Foundation (https://cdiff.org/). From that moment, advocacy turned concre...

Decoding Real-World Evidence: Beyond Clinical Trials with Manfred Stapff 10.09.2025

Send us Fan Mail What if millions of electronic health records could transform how we understand medicine? In this thought-provoking conversation with Dr. Manfred Stapff, physician and real-world evidence pioneer, we uncover how anonymized patient data is revolutionizing healthcare research. Dr. Stapff reveals how the 21st Century Cures Act dramatically accelerated electronic medical record adopti...

Democratizing Drug Development Through AI-Native Platforms with Ilya Burkov 27.08.2025

Send us Fan Mail Cloud computing is transforming biotech by offering purpose-built infrastructure that supports AI-driven drug discovery and development while meeting strict regulatory requirements. Dr. Ilya Burkov explains how Nebius provides full-stack solutions that democratize access to powerful technology, enabling researchers to achieve breakthroughs that previously required generations. • C...

Incorruptible Evidence: Blockchain's Promise for Faster Drug Approvals w. Dominik Lysek 13.08.2025

Send us Fan Mail Dominik Lysek, CEO of PharmaTrail, explains how blockchain technology can solve trust issues in clinical trials by providing an incorruptible audit trail that verifies data integrity. This solution could significantly accelerate the time required for regulatory approvals, partnerships, and acquisitions, ultimately getting treatments to patients faster. • Blockchain provides a comp...

Słuchaj podcastu Lab to Lives w Replaio

Radio i podcasty w jednej aplikacji - za darmo, bez zakładania konta. Zainstaluj już dziś i nie przegap premiery

Pobierz z Google Play

Replaio nie jest wydawcą podcastów; nazwy audycji, okładki i audio należą do ich autorów i są rozpowszechniane przez publiczne kanały RSS